HLA-B27 Specific Neutra™ Antibody Products
Product listAccelerate Your Research and Development!
Are you currently facing challenges in accurately detecting HLA-B27, diagnosing HLA-B27-associated spondyloarthropathies, or developing highly specific assays for immune-mediated conditions? HLA-B27 Specific Antibody Products from Creative Biolabs help you achieve precise and reliable HLA-B27 detection, enabling robust research into autoimmune mechanisms and the development of advanced diagnostic tools through high-specificity antibodies and immunoassay solutions.
Contact our team to get an inquiry now!
Introduction of HLA-B27
Human Leukocyte Antigen B27 (HLA-B27) is a specific allele of the Major Histocompatibility Complex (MHC) Class I gene, located on chromosome 6. MHC Class I molecules are crucial components of the adaptive immune system, responsible for presenting intracellular antigenic peptides to cytotoxic T lymphocytes (CD8+ T cells). This presentation is fundamental for immune surveillance, allowing the immune system to recognize and eliminate virally infected cells or tumor cells.
Structurally, HLA-B27, like other MHC Class I molecules, is a heterodimer composed of a heavy α-chain (encoded by the HLA-B gene) non-covalently associated with a light chain, β2-microglobulin. The α-chain possesses three extracellular domains (α1, α2, α3), a transmembrane portion, and a cytoplasmic end. The α1 and α2 domains constitute the peptide-binding cleft, accommodating peptides typically spanning 8-11 residues.
Fig. 1 Factors contributing to HLA-B27 associated gut inflammation in SpA.1
HLA-B27 is particularly significant due to its strong genetic association with a group of chronic inflammatory diseases known as spondyloarthropathies (SpA). The most prominent of these is ankylosing spondylitis (AS), a debilitating condition primarily affecting the spine and sacroiliac joints. Additional linked disorders encompass reactive arthropathy, psoriatic arthritis, and inflammatory bowel disease-related spondyloarthropathy. While the exact mechanism by which HLA-B27 contributes to these diseases is still under investigation, leading hypotheses include molecular mimicry, abnormal peptide presentation, and the formation of HLA-B27 heavy chain homodimers that can trigger inflammatory responses. Its presence serves as a significant genetic risk factor and a valuable diagnostic marker for these conditions.
Antibodies Against HLA-B27
Antibodies targeting the HLA-B27 antigen are indispensable tools in both clinical diagnostics and immunological research. These antibodies are designed to specifically recognize and bind to distinct epitopes on the HLA-B27 molecule, enabling its accurate detection and characterization. In clinical settings, anti-HLA-B27 antibodies are primarily used for diagnostic screening of individuals suspected of having spondyloarthropathies, as the presence of HLA-B27 is a strong indicator, although not exclusive, for these conditions.
In research, these antibodies enable diverse applications:
- Flow Cytometry (FACS): This is the most common and robust application for HLA-B27 typing. Antibodies conjugated with fluorochromes allow for rapid and high-throughput identification and quantification of HLA-B27 positive cells from peripheral blood or other biological samples. This is vital for disease detection and for analyzing immune cell subsets in autoimmune disorders.
- Immunohistochemistry (IHC) and Immunofluorescence (IF): These techniques enable the visualization of HLA-B27 expression on cell surfaces in tissue sections or cultured cells, providing insights into its cellular localization and distribution in various tissues, including inflamed joints or gut biopsies.
- Western Blotting (WB): Used to confirm the presence and molecular weight of the HLA-B27 heavy chain in cell lysates, particularly useful for validating expression in cell lines or studying post-translational modifications.
- ELISA: Can be adapted for quantitative detection of soluble HLA-B27 or for screening purposes in research settings, though less common for routine clinical typing compared to flow cytometry.
These applications collectively support the diagnosis of HLA-B27-associated diseases, research into their pathogenesis, and the development of new therapeutic strategies by allowing precise identification and study of the HLA-B27 molecule.
Why Choose Us?
Choosing Creative Biolabs for your HLA-B27 Specific Antibody needs means partnering with a leader committed to scientific excellence and customer success. Our dedication to quality and innovation sets us apart:
- Unparalleled Specificity and Sensitivity: Our antibodies are rigorously validated to ensure high specificity for the HLA-B27 antigen, minimizing cross-reactivity with other HLA alleles and delivering accurate, reliable results even at low expression levels.
- Comprehensive Validation: Each antibody undergoes extensive validation across multiple applications (Flow Cytometry, ELISA, Western Blotting, IHC, IF) to guarantee performance and reproducibility in diverse experimental and clinical settings.
- Expertise and Support: With over 20 years of experience in antibody development and immunology, our team of biology specialists provides expert technical support and guidance, ensuring you maximize the potential of our products in your research and diagnostic workflows.
- Customization Capabilities: Beyond our catalog, we offer custom antibody development services to meet your unique project requirements, including specific host species, affinity, and conjugation needs for specialized applications.
FAQs
Q: What is the principal medical application for detecting this targeted antigen?
A: The primary clinical utility is its strong association with a group of inflammatory conditions, particularly ankylosing spondylitis. While not diagnostic on its own, a positive test result, especially in conjunction with clinical symptoms, can significantly aid in the early diagnosis and classification of these diseases.
Q: Can a positive test result for this antigen definitively diagnose an autoimmune disease?
A: No, a positive test result for this antigen does not definitively diagnose an autoimmune disease. It indicates a genetic predisposition or increased risk. Diagnosis requires a combination of clinical symptoms, physical examination findings, imaging studies (like X-rays or MRI), and other laboratory tests.
Q: How do antibody-based detection methods for this antigen compare to genetic testing methods?
A: Antibody-based methods typically detect the protein expressed on the cell surface, which is useful for routine clinical screening, especially via flow cytometry due to its speed and efficiency. Genetic testing directly identifies the gene allele, offering definitive genetic confirmation. Both methods serve complementary roles depending on the diagnostic or research objective.
Q: Are there any factors that can interfere with the accuracy of antibody-based detection for this antigen?
A: Potential interfering factors can include improper sample handling, presence of interfering substances in the sample, or cross-reactivity with other closely related antigens if the antibody lacks sufficient specificity. Rigorous assay validation and adherence to sample preparation protocols are crucial to minimizing such interferences.
Access the Creative Biolabs Edge – Request Your Quote Now
REFERENCE
- Gill, Tejpal, and James T Rosenbaum. “Putative Pathobionts in HLA-B27-Associated Spondyloarthropathy.” Frontiers in immunology vol. 11 586494. 18 Jan. 2021, DOI:10.3389/fimmu.2020.586494. Distributed under Open Access license CC BY 4.0, without modification.
